Acurx Pharmaceuticals, Inc.
$2.36
▼
-5.4%
2026-04-21 05:04:00
www.acurxpharma.com
NCM: ACXP
Explore Acurx Pharmaceuticals, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$6.79 M
Current Price
$2.36
52W High / Low
$21 / $1.33
Stock P/E
—
Book Value
$2.24
Dividend Yield
—
ROCE
-153.59%
ROE
-2.71%
Face Value
—
EPS
$-5.32
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
4
Beta
-1.92
Debt / Equity
—
Current Ratio
3.18
Quick Ratio
3.18
Forward P/E
-1.19
Price / Sales
—
Enterprise Value
$-0.1 M
EV / EBITDA
—
EV / Revenue
—
Rating
None
Target Price
$17
EPS Forecast (FY)
—
Pros
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Biohaven Ltd. | $10.82 | — | $1.65 B | — | -222.16% | -3.11% | $24.06 / $7.48 | $0.39 |
| 2. | Replimune Group, Inc. | $2.07 | — | $170.93 M | — | -53.14% | -90.88% | $13.24 / $1.5 | $2.64 |
| 3. | Zenas BioPharma, Inc. | $20.9 | — | $1.28 B | — | -65.85% | -1.36% | $44.6 / $8.09 | $4.44 |
| 4. | Larimar Therapeutics, Inc. | $4.81 | — | $499.68 M | — | -212.84% | -1.33% | $6.42 / $1.73 | $0.94 |
| 5. | Fractyl Health, Inc. | $0.58 | — | $90.33 M | — | -93.93% | -7.44% | $3.03 / $0.38 | $0.06 |
| 6. | Rein Therapeutics Inc. | $1.83 | — | $51.31 M | — | -121.99% | -1.4% | $2.4 / $1.02 | $-1.02 |
| 7. | Zymeworks Inc. | $27.85 | — | $1.98 B | — | -30.42% | -26.72% | $28.49 / $10.86 | $3.6 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -1.62 M | -2.03 M | -2.27 M | -2.15 M | -2.78 M | — |
| Net Profit | -1.58 M | -1.99 M | -2.25 M | -2.15 M | -2.78 M | — |
| EPS in Rs | -0.55 | -0.7 | -0.79 | -0.75 | -0.97 | -3.45 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -8.09 M | -14.12 M | -14.58 M | -12.09 M |
| Net Profit | -7.97 M | -14.1 M | -14.58 M | -12.09 M |
| EPS in Rs | -2.79 | -4.94 | -5.11 | -4.24 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 7.69 M | 3.86 M | 7.71 M | 9.38 M |
| Total Liabilities | 2.42 M | 3.24 M | 3.04 M | 2.06 M |
| Equity | 5.27 M | 0.62 M | 4.67 M | 7.32 M |
| Current Assets | 7.69 M | 3.86 M | 7.71 M | 9.38 M |
| Current Liabilities | 2.42 M | 3.24 M | 3.04 M | 2.06 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -6.79 M | -10.38 M | -9.8 M | -7.54 M |
| Investing CF | — | — | — | — |
| Financing CF | 10.64 M | 6.62 M | 8.16 M | 3.7 M |
| Free CF | -6.79 M | -10.38 M | -9.8 M | -7.54 M |
| Capex | — | — | — | — |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | 3.26% | -20.55% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2025-08-05 | 1:0.05 |